RxDoctor Payments Data

Eydie Miller, MD

Ophthalmology · Philadelphia, PANPI 1780614875

Payments from drug & device makers

$65,740in general payments, 2019–2025

Across 114 payments — averaging $576.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$30K
  • AbbVie$19K
  • Alcon$6K
  • Amgen$5K
  • Thea Pharma Inc.$4K
  • Sun Pharmaceutical Industries Inc.$332
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$39,61772%
  • Speaking & faculty fees$5,75010%
  • Travel & lodging$4,8499%
  • Food & beverage$5,0829%
  • Education$870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,740 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$65,127
Medicare patients
368
Services billed
1,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost73$36,250
RhopressaNetarsudil Mesylate57$25,026
Travoprost63$10,341
Brimonidine Tartrate165$8,029
Alphagan PBrimonidine Tartrate24$6,534
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat199$5,438
Latanoprost442$5,131
Timolol Maleate135$3,645
Dorzolamide-TimololDorzolamide/Timolol/Pf11$3,238
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol19$3,085
Prednisolone Acetate61$2,229
Bimatoprost17$1,631
Dorzolamide Hcl58$1,160
Pilocarpine Hcl13$928
Ketorolac Tromethamine43$889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P$18,838$42,78497 claims
Aerie Pharmaceuticals, Inc.Rhopressa$29,730$25,02657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →